Cargando…
The effect of 12 weeks Anethum graveolens (dill) on metabolic markers in patients with metabolic syndrome; a randomized double blind controlled trial
BACKGROUND: The clustering of metabolic abnormalities defined as metabolic syndrome is now both a public health and a clinical problem .While interest in herbal medicine has greatly increased, lack of human evidence to support efficacies shown in animals does exist. This clinical trial study designe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3555834/ https://www.ncbi.nlm.nih.gov/pubmed/23351341 http://dx.doi.org/10.1186/2008-2231-20-47 |
_version_ | 1782257088233209856 |
---|---|
author | Mansouri, Masoume Nayebi, Neda keshtkar, Abasali Hasani-Ranjbar, Shirin Taheri, Eghbal Larijani, Bagher |
author_facet | Mansouri, Masoume Nayebi, Neda keshtkar, Abasali Hasani-Ranjbar, Shirin Taheri, Eghbal Larijani, Bagher |
author_sort | Mansouri, Masoume |
collection | PubMed |
description | BACKGROUND: The clustering of metabolic abnormalities defined as metabolic syndrome is now both a public health and a clinical problem .While interest in herbal medicine has greatly increased, lack of human evidence to support efficacies shown in animals does exist. This clinical trial study designed to investigate whether herbal medicine, Anethum graveolens (dill) extract, could improve metabolic components in patients with metabolic syndrome. METHODS: A double-blind, randomized, placebo-controlled trial using a parallel design was conducted. 24 subjects who had metabolic syndrome diagnostic criteria (update of ATP III) were randomly assigned to either dill extract (n = 12) or placebo (n = 12) for 3 months. RESULTS: Across lipid component of metabolic syndrome, no significant differences in triglyceride (TG) concentration and high density lipoprotein cholesterol were seen between the two groups. However TG improved significantly from baseline (257.0 vs. 201.5p = 0.01) with dill treatment but such a significant effect was not observed in placebo group. Moreover, no significant differences in waist circumference, blood pressure and fasting blood sugar were seen between two groups after 3 months follow up period. CONCLUSION: In this small clinical trial in patients with metabolic syndrome, 12 weeks of dill extract treatment had a beneficial effect in terms of reducing TG from baseline. However dill treatment was not associated with a significant improvement in metabolic syndrome related markers compared to control group. Larger studies might be required to prove the efficacy and safety of long-term administration of dill to resolve metabolic syndrome components. |
format | Online Article Text |
id | pubmed-3555834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35558342013-01-31 The effect of 12 weeks Anethum graveolens (dill) on metabolic markers in patients with metabolic syndrome; a randomized double blind controlled trial Mansouri, Masoume Nayebi, Neda keshtkar, Abasali Hasani-Ranjbar, Shirin Taheri, Eghbal Larijani, Bagher Daru Research Article BACKGROUND: The clustering of metabolic abnormalities defined as metabolic syndrome is now both a public health and a clinical problem .While interest in herbal medicine has greatly increased, lack of human evidence to support efficacies shown in animals does exist. This clinical trial study designed to investigate whether herbal medicine, Anethum graveolens (dill) extract, could improve metabolic components in patients with metabolic syndrome. METHODS: A double-blind, randomized, placebo-controlled trial using a parallel design was conducted. 24 subjects who had metabolic syndrome diagnostic criteria (update of ATP III) were randomly assigned to either dill extract (n = 12) or placebo (n = 12) for 3 months. RESULTS: Across lipid component of metabolic syndrome, no significant differences in triglyceride (TG) concentration and high density lipoprotein cholesterol were seen between the two groups. However TG improved significantly from baseline (257.0 vs. 201.5p = 0.01) with dill treatment but such a significant effect was not observed in placebo group. Moreover, no significant differences in waist circumference, blood pressure and fasting blood sugar were seen between two groups after 3 months follow up period. CONCLUSION: In this small clinical trial in patients with metabolic syndrome, 12 weeks of dill extract treatment had a beneficial effect in terms of reducing TG from baseline. However dill treatment was not associated with a significant improvement in metabolic syndrome related markers compared to control group. Larger studies might be required to prove the efficacy and safety of long-term administration of dill to resolve metabolic syndrome components. BioMed Central 2012-10-04 /pmc/articles/PMC3555834/ /pubmed/23351341 http://dx.doi.org/10.1186/2008-2231-20-47 Text en Copyright ©2012 Mansouri et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Mansouri, Masoume Nayebi, Neda keshtkar, Abasali Hasani-Ranjbar, Shirin Taheri, Eghbal Larijani, Bagher The effect of 12 weeks Anethum graveolens (dill) on metabolic markers in patients with metabolic syndrome; a randomized double blind controlled trial |
title | The effect of 12 weeks Anethum graveolens (dill) on metabolic markers in patients with metabolic syndrome; a randomized double blind controlled trial |
title_full | The effect of 12 weeks Anethum graveolens (dill) on metabolic markers in patients with metabolic syndrome; a randomized double blind controlled trial |
title_fullStr | The effect of 12 weeks Anethum graveolens (dill) on metabolic markers in patients with metabolic syndrome; a randomized double blind controlled trial |
title_full_unstemmed | The effect of 12 weeks Anethum graveolens (dill) on metabolic markers in patients with metabolic syndrome; a randomized double blind controlled trial |
title_short | The effect of 12 weeks Anethum graveolens (dill) on metabolic markers in patients with metabolic syndrome; a randomized double blind controlled trial |
title_sort | effect of 12 weeks anethum graveolens (dill) on metabolic markers in patients with metabolic syndrome; a randomized double blind controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3555834/ https://www.ncbi.nlm.nih.gov/pubmed/23351341 http://dx.doi.org/10.1186/2008-2231-20-47 |
work_keys_str_mv | AT mansourimasoume theeffectof12weeksanethumgraveolensdillonmetabolicmarkersinpatientswithmetabolicsyndromearandomizeddoubleblindcontrolledtrial AT nayebineda theeffectof12weeksanethumgraveolensdillonmetabolicmarkersinpatientswithmetabolicsyndromearandomizeddoubleblindcontrolledtrial AT keshtkarabasali theeffectof12weeksanethumgraveolensdillonmetabolicmarkersinpatientswithmetabolicsyndromearandomizeddoubleblindcontrolledtrial AT hasaniranjbarshirin theeffectof12weeksanethumgraveolensdillonmetabolicmarkersinpatientswithmetabolicsyndromearandomizeddoubleblindcontrolledtrial AT taherieghbal theeffectof12weeksanethumgraveolensdillonmetabolicmarkersinpatientswithmetabolicsyndromearandomizeddoubleblindcontrolledtrial AT larijanibagher theeffectof12weeksanethumgraveolensdillonmetabolicmarkersinpatientswithmetabolicsyndromearandomizeddoubleblindcontrolledtrial AT mansourimasoume effectof12weeksanethumgraveolensdillonmetabolicmarkersinpatientswithmetabolicsyndromearandomizeddoubleblindcontrolledtrial AT nayebineda effectof12weeksanethumgraveolensdillonmetabolicmarkersinpatientswithmetabolicsyndromearandomizeddoubleblindcontrolledtrial AT keshtkarabasali effectof12weeksanethumgraveolensdillonmetabolicmarkersinpatientswithmetabolicsyndromearandomizeddoubleblindcontrolledtrial AT hasaniranjbarshirin effectof12weeksanethumgraveolensdillonmetabolicmarkersinpatientswithmetabolicsyndromearandomizeddoubleblindcontrolledtrial AT taherieghbal effectof12weeksanethumgraveolensdillonmetabolicmarkersinpatientswithmetabolicsyndromearandomizeddoubleblindcontrolledtrial AT larijanibagher effectof12weeksanethumgraveolensdillonmetabolicmarkersinpatientswithmetabolicsyndromearandomizeddoubleblindcontrolledtrial |